The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13-MAPK-YWHAE signaling pathway.
Yingcong WangSanfeng DongKe HuLi XuQilin FengBo LiGuangli WangGege ChenBibo ZhangXinyan JiaZhijian XuXuejie GaoHui ZhangYongsheng XieMeiling LuShuaikang ChangDongliang SongXiaosong WuQi JiaHuabin ZhuJinfeng ZhouWeiliang ZhuJumei ShiPublished in: Journal of translational medicine (2023)
DCZ5417 suppresses MM progression in vitro, in vivo, and in primary cells from drug-resistant patients, affecting cell proliferation by targeting TRIP13, destroying the TRIP13/YWHAE complex, and inhibiting ERK/MAPK signaling. These results imply a new and effective therapeutic strategy for MM treatment.
Keyphrases
- signaling pathway
- drug resistant
- pi k akt
- cell proliferation
- induced apoptosis
- epithelial mesenchymal transition
- multidrug resistant
- end stage renal disease
- multiple myeloma
- acinetobacter baumannii
- ejection fraction
- newly diagnosed
- chronic kidney disease
- oxidative stress
- peritoneal dialysis
- cystic fibrosis
- patient reported outcomes